WESTON, Fla. - ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA), a biopharmaceutical company specializing in the development of drugs for inflammatory and renal diseases, has drawn attention to recent research findings that could have implications for treating atherosclerosis (AS) in diabetic patients.
The data, published in the journal Biochemical and Biophysical Research Communications, suggests that inhibiting the NLRP3 inflammasome pathway could reduce atherosclerotic lesions and improve plaque stability in a diabetic context.
The study compared serum and coronary artery tissues from patients with coronary artery disease (CAD), with and without diabetes, and utilized diabetic mouse models to assess the effects of NLRP3 inhibition. It found that patients with both CAD and diabetes had higher levels of NLRP3 and associated inflammatory markers than those with CAD alone. In diabetic mice, inhibition of NLRP3 led to a significant decrease in the atherosclerotic plaque/vessel area ratio and reduced levels of proinflammatory cytokines.
ZyVersa is developing IC 100, a monoclonal antibody targeting inflammasome ASC and ASC specks from multiple types of inflammasomes, including NLRP3. IC 100 is designed to block the initiation and perpetuation of inflammation that promotes AS and its progression. The company plans to initiate preclinical trials of IC 100 in an animal model of atherosclerosis in the first half of this year.
Stephen C. Glover, Co-founder, Chairman, CEO, and President of ZyVersa, expressed optimism about the published data and the potential of IC 100 to control AS development and progression in patients with diabetes. Diabetes is recognized as a leading cause of morbidity and mortality globally, and AS is the most common cause of death among diabetic patients.
This article is based on a press release statement from ZyVersa Therapeutics.
InvestingPro Insights
ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) is navigating a challenging financial landscape, as reflected in the real-time metrics from InvestingPro. The company holds a market capitalization of just $5.41 million USD, indicative of its small-cap status in the biopharmaceutical industry. With a negative adjusted P/E ratio over the last twelve months as of Q4 2023, at -0.28, ZyVersa's profitability is under scrutiny. Moreover, the company's Price/Book ratio during the same period stands at 0.49, suggesting that the market values the company at less than the net value of its assets.
Analyzing the company's stock performance reveals a significant downturn, with a 1-year price total return of -98.9% as of the latest data. This steep decline is further emphasized by a 6-month price total return of -85.91%, highlighting the stock's poor performance over recent months. Investors considering ZyVersa should note that the stock has fared poorly, not only in the short term but also over the last decade, according to InvestingPro Tips. Additionally, the company's short-term obligations exceed its liquid assets, which could present liquidity challenges.
For those interested in a deeper dive into the financial health and stock performance of ZyVersa, InvestingPro offers additional insights. There are over 10 InvestingPro Tips available, which can provide a more comprehensive understanding of the company's position and future outlook. Readers can access these tips at InvestingPro's ZyVersa page. Moreover, by using the coupon code PRONEWS24, readers can get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking a wealth of investment knowledge and expertise.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.